Agios Pharmaceuticals, Inc. (AGIO)
AGIO Stock Price Chart
Explore Agios Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AGIO price movements and trends.
AGIO Company Profile
Discover essential business fundamentals and corporate details for Agios Pharmaceuticals, Inc. (AGIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Jul 2013
Employees
486.00
Website
https://www.agios.comCEO
Brian Goff
Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO Financial Timeline
Browse a chronological timeline of Agios Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$1.66, while revenue estimate is $26.07m.
Earnings released on 29 Apr 2026
EPS came in at -$1.69 surpassing the estimated -$1.81 by +6.63%, while revenue for the quarter reached $20.75m , beating expectations by +55.98%.
Earnings released on 12 Feb 2026
EPS came in at -$1.85 surpassing the estimated -$1.97 by +6.09%, while revenue for the quarter reached $19.97m , beating expectations by +65.14%.
Earnings released on 30 Oct 2025
EPS came in at -$1.78 surpassing the estimated -$1.93 by +7.77%, while revenue for the quarter reached $12.88m , beating expectations by +10.09%.
Earnings released on 31 Jul 2025
EPS came in at -$1.93 falling short of the estimated -$1.74 by -10.92%, while revenue for the quarter reached $12.46m , beating expectations by +21.16%.
Earnings released on 1 May 2025
EPS came in at -$1.55 surpassing the estimated -$1.80 by +13.89%, while revenue for the quarter reached $8.73m , missing expectations by -12.62%.
Earnings released on 13 Feb 2025
EPS came in at -$1.74 falling short of the estimated -$1.69 by -2.96%, while revenue for the quarter reached $10.73m , beating expectations by +14.79%.
Earnings released on 31 Oct 2024
EPS came in at $4.20 falling short of the estimated $16.69 by -74.84%, while revenue for the quarter reached $8.96m , missing expectations by -3.30%.
Earnings released on 1 Aug 2024
EPS came in at -$1.69 falling short of the estimated -$1.58 by -6.96%, while revenue for the quarter reached $8.62m , missing expectations by -7.47%.
Earnings released on 2 May 2024
EPS came in at -$1.45 surpassing the estimated -$1.64 by +11.59%, while revenue for the quarter reached $8.19m , missing expectations by -16.01%.
Earnings released on 15 Feb 2024
EPS came in at -$1.72 falling short of the estimated -$1.64 by -4.88%, while revenue for the quarter reached $7.10m , missing expectations by -10.34%.
Earnings released on 2 Nov 2023
EPS came in at -$1.64 surpassing the estimated -$1.69 by +2.96%, while revenue for the quarter reached $7.40m , missing expectations by -1.69%.
Earnings released on 3 Aug 2023
EPS came in at -$1.51 surpassing the estimated -$1.60 by +5.63%, while revenue for the quarter reached $6.71m , beating expectations by +3.90%.
Earnings released on 4 May 2023
EPS came in at -$1.47 surpassing the estimated -$1.72 by +14.53%, while revenue for the quarter reached $5.61m , beating expectations by +7.25%.
Earnings released on 23 Feb 2023
EPS came in at $0.67 surpassing the estimated -$1.59 by +142.14%, while revenue for the quarter reached $4.31m , missing expectations by -4.97%.
Earnings released on 3 Nov 2022
EPS came in at -$1.49 surpassing the estimated -$1.75 by +14.86%, while revenue for the quarter reached $3.52m , missing expectations by -33.26%.
Earnings released on 4 Aug 2022
EPS came in at -$1.68 surpassing the estimated -$1.78 by +5.62%, while revenue for the quarter reached $5.58m , beating expectations by +92.12%.
Earnings released on 5 May 2022
EPS came in at -$1.74 surpassing the estimated -$1.85 by +5.95%, while revenue for the quarter reached $832.00k , missing expectations by -3.72%.
Earnings released on 24 Feb 2022
EPS came in at -$1.81 falling short of the estimated -$1.71 by -5.85%, while revenue for the quarter reached $41.41 , missing expectations by -100.00%.
Earnings released on 3 Nov 2021
EPS came in at -$1.48 surpassing the estimated -$1.61 by +8.07%.
Earnings released on 29 Jul 2021
EPS came in at -$1.36 surpassing the estimated -$1.39 by +2.16%, while revenue for the quarter reached $37.35m .
AGIO Stock Performance
Access detailed AGIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
